News
Three patients with a muscle-wasting disease died from liver failure after taking the therapy, Elevidys, or a similar ...
The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...
The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.
Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular dystrophy.
The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene therapy for Duchenne muscular dystrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback